Crossmark

Efficacy and tolerability of first-line treatment regimens for extensive-stage small cell lung cancer – a grade-assessed network meta-analysis of randomized controlled trials

Crossref DOI link: https://doi.org/10.1186/s12885-025-15439-4

Published Online: 2026-02-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Najah, Qasi

Makhlouf, Hamdy A. https://orcid.org/0009-0008-0907-4475
Osman, Ahmed S. A. https://orcid.org/0009-0002-2871-9925
Almosilhy, Nereen A. https://orcid.org/0000-0003-2437-7059
Abusalah, Mariam A. https://orcid.org/0009-0006-1007-5550
Abuhlaiga, Maaly A. https://orcid.org/0000-0003-4082-965X
Qutob, Israa Ahmed

Abdelgawad, Hussien Ahmed H.
License Information

Text and Data Mining valid from 2026-02-27

Version of Record valid from 2026-03-02
More Information

Article History

Received: 16 August 2025

Accepted: 5 December 2025

First Online: 27 February 2026

Declarations

:

: Not applicable. This study is a systematic review and network meta-analysis of previously published randomized controlled trials and did not involve the collection of new human or animal data.

: Not applicable.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below